CLINICAL_TRIALS
trial_result
· 2012-03-19
Clinical Trial Update: Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma [Phase 2]
Summary
Phase 2 study of AG-013736 (cediranib) in patients with metastatic renal cell carcinoma completed; results were posted in 2012.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Kidney Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2012-03-19